Heart failure & cardiomyopathies

Type 2 diabetes in heart failure with preserved and mildly reduced ejection fraction: insights from the REDUCE-LAP-HF II trial

ESC Heart FailPublished prospectively phenotyped cohort

Authors' conclusion

HFpEF/HFmrEF patients with T2DM experience adverse myocardial remodelling, impaired biventricular function, adverse central haemodynamics, and worse clinical outcomes independent of obesity. These findings indicate that T2DM confers additional metabolic burden to the myocardium, beyond that attributable to obesity alone.

Study context

Population
Patients with HFpEF/HFmrEF undergoing invasive haemodynamic assessmentsham-control arm of the REDUCE LAP-HF II trial
Participants
312 patients
Exposure
T2DM vs no T2DM, adjusted for body mass index (BMI) and clinical covariates
Outcome
Prevalence of T2DM
Methodological detailssham-control arm of the REDUCE LAP-HF II trial, invasive haemodynamic assessment, multivariable models adjusted for BMI and clinical covariates
  • Sham-control arm of the REDUCE LAP-HF II trial
  • Invasive haemodynamic assessment
  • Multivariable models adjusted for BMI and clinical covariates

Main finding

As reported in the abstract

T2DM present

37%

Observational data: associations, not effects.

Further findings

Obesity · more prevalent in those with T2DM

P = 0.032

Heart failure (HF) events or cardiovascular (CV) death · median of 4.0-year (2.5-5.0) follow-up

Adjusted hazard ratio (95% CI)
T2DMIncreased risk with T2DM; driven by HF events1.96 (1.28–3.00)
Obesity — Obesity present overall
62%

Cardiac structure, function and haemodynamics

T2DM independently associated with greater left ventricular mass, lower EF, impaired left ventricular global longitudinal strain, reduced right ventricular free-wall strain, and higher resting filling pressures
  • After adjustment for BMI

HF events or CV death · median of 4.0-year (2.5-5.0) follow-up

BMI was not independently prognostic

Original publication

Type 2 diabetes in heart failure with preserved and mildly reduced ejection fraction: insights from the REDUCE-LAP-HF II trial. ESC Heart Fail. Published 11 August 2026. doi:10.1093/eschf/xvag210

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.